Resultados de Búsqueda por Autor

artículo

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis...

Publicado por
Regan, MM, Walley, BA, Francis, PA, Fleming, GF, Láng, I, Gómez, HL, Colleoni, M, Tondini, C, Pinotti, G, Salim, M, Spazzapan, S, Parmar, V, Ruhstaller, T, Abdi, EA, Gelber, RD, Coates, AS, Goldhirsch, A, Pagani, O

Publicado 2017

Enlace

Background: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation. Design and methods: We analyzed 1872 patients enrolled in the randomized phase III TEXT and SOFT trials who received adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer and upon randomization to an OFS-containing adjuvant endocrine therapy, initiated gonadotropin-releasing-hormone-agonist triptorelin. Breast cancer-free interval (BCFI) was compared between patients who received OFS concurrently with chemotherapy in TEXT (n = 1242) versus sequentially post-chemotherapy in SOFT (n = 630). Because timing of trial enrollment relative to adjuvant chemotherapy differed, w...

artículo

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Publicado por
Saha, P, Regan, MM, Pagani, O, Francis, PA, Walley, BA, Ribi, K, Bernhard, J, Luo, W, Gómez, HL, Burstein, HJ, Parmar, V, Torres, R, Stewart, J, Bellet, M, Perelló, A, Dane, F, Moreira, A, Vorobiof, D, Nottage, M, Price, KN, Coates, AS, Goldhirsch, A, Gelber, RD, Colleoni, M, Fleming, GF, SOFT TEXT Investigators, International Breast Cancer Study Group

Publicado 2017

Enlace

Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT and TEXT, alongside data from the cohort of older premenopausal women. Results For 240 human epidermal growth factor receptor 2-negative patients younger than 35 years enrolled in SOFT after receivin...